Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has received a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.1667.

CNTX has been the topic of several research reports. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Tuesday, March 24th. Wall Street Zen lowered shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Maxim Group decreased their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Piper Sandler boosted their price objective on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Finally, Guggenheim reissued a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th.

Institutional Investors Weigh In On Context Therapeutics

Several large investors have recently made changes to their positions in CNTX. Virtu Financial LLC bought a new stake in Context Therapeutics in the fourth quarter worth approximately $43,000. Sanctuary Advisors LLC acquired a new position in shares of Context Therapeutics during the 1st quarter worth about $51,000. Quadrature Capital Ltd acquired a new stake in Context Therapeutics in the 4th quarter worth $68,000. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics in the third quarter valued at $100,000. Finally, XTX Topco Ltd raised its stake in shares of Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

NASDAQ:CNTX opened at $0.65 on Monday. The stock has a market cap of $60.06 million, a price-to-earnings ratio of -1.56 and a beta of 1.75. Context Therapeutics has a 1 year low of $0.55 and a 1 year high of $3.62. The business has a fifty day moving average of $1.77 and a 200-day moving average of $2.05.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. On average, equities research analysts predict that Context Therapeutics will post -0.35 EPS for the current year.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.